Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06203652

The Pathogenesis and Prognostic Factors of Lymphoma

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Hodgkin Disease Hodgkin Lymphoma Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Non-Hodgkin Lymphoma

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongshan Hospital，Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location status: Recruiting

Location contact

Peng Liu, Ph.D

CONTACT

[email protected]

+862164041990 ext. 2025

Peng Liu, Ph.D

PRINCIPAL_INVESTIGATOR

About this study

Lymphoma is a highly common malignant tumor in Asia. This study aims to observe and describe the clinical and genetic charateristics of Chinese lymphoma patients, and to explore the relationship between those charateristics and pathogenesis and prognostic factors in the real-world population. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027.
  • Patients with complete diagnostic, treatment and follow-up records.
  • Fully comprehension and signature of the informed consent form (ICF) for participation.

Exclusion criteria

  • Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.
  • Severe mental illness.
  • Patients deemed unsuitable for inclusion by the investigator.

Treatment and study plan

Real-world regimen

Other

The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on

Primary outcomes

  1. OS

    Time frame: Baseline up to data cut-off (Up to approximately 20 years)

    Overall survival (OS) refers to the time from receiving the first dose to death from any cause

Secondary outcomes

  1. PFS

    Time frame: Baseline up to data cut-off (Up to approximately 20 years)

    Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death from any cause, whichever occurs first.

Study contacts

Contact information is provided by the study sponsor or research team.

Peng Liu, Ph.D

CONTACT

[email protected]

+862164041990 ext. 2025

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2028
First posted
Jan 12, 2024
Registry last updated
Jan 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.